Avance Clinical Wins International Health Award for Biotech CRO Services
Avance Clinical Wins International Health Award for Biotech CRO Services

SYDNEY, AU, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier’s Export Awards – International Health category. The award recognises excellence in clinical services exports. Avance Clinical CEO Yvonne Lungershausen The Premier of South Australia Peter Malinauskas, and Minister... » read more

Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC

ADELAIDE, AUS, Apr 19, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence. Avance Clinical has undergone significant expansion in recent years, including new offices in... » read more

Avance Clinical墨尔本办公室正式启动
Avance Clinical墨尔本办公室正式启动

MELBOURNE, Mar 31, 2022 – (亚太商讯 via SEAPRWire.com) – Avance Clinical是澳大利亚本地最大的CRO，致力于协助世界各地的生物科技以及制药公司完成早期临床...

Avance Clinical Announces New Office Opening in Melbourne
Avance Clinical Announces New Office Opening in Melbourne

MELBOURNE, Mar 31, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Melbourne to support its growing clinical team in the greater Melbourne region. The Avance Clinical team in Melbourne The formal opening event was attended by all the... » read more

Avance Clinical悉尼办公室正式启动
Avance Clinical悉尼办公室正式启动

SYDNEY, Mar 2, 2022 – (亚太商讯 via SEAPRWire.com) – Avance Clinical是澳大利亚本地最大的CRO，致力于协助世界各地的生物科技以及制药公司完成早期临床研究。目...

Avance Clinical Announces New Office Opening in Sydney
Avance Clinical Announces New Office Opening in Sydney

SYDNEY, Mar 2, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region. Avance Clinical’s CEO Yvonne Lungershausen said: “We continue to offer a hybrid working environment for... » read more

Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

ADELAIDE, AUS, Jan 18, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. Avance... » read more

Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain

ADELAIDE, AUS, Oct 19, 2021 – (ACN Newswire) – Avance Clinical, the largest premium Australian CRO for international biotechs, is pleased to share the news that its client XWPharma Ltd. has announced dosing of subjects in its first-in-human study evaluating XW10508, the Company’s novel, patented, glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy for... » read more

Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia
Avance Clinical Congratulates Client Tetherex Pharmaceuticals on Initiation of Dosing in a Phase 1 Clinical Study Using a Novel Single-Cycle Adenovirus Vaccine Strategy in Australia

ADELAIDE, AUS, Jul 9, 2021 – (ACN Newswire via SEAPRWire.com) – The largest Australian full-service CRO for international biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical today congratulated client Tetherex Pharmaceuticals on first patient dosing for its Phase 1 vaccine clinical trial. Tetherex Pharmaceuticals, Inc. is a privately held, clinical... » read more